Sir Roy on LCNTDR's role in the NTD endgame
Earlier this month LCNTDR’s Prof Sir Roy Anderson spoke to the Infectious Diseases Hub about the work of LCNTDR and the role it has to play in the control and elimination of NTDs.
Infectious Diseases Hub is a new online resource for infectious diseases information and research. The website aims to provide up-to-date news, peer-reviewed articles, interviews and comment on all aspects of virology and microbiology.
In the below interviews Sir Roy highlights some of the research projects currently being undertaken as part of the LCNTDR, such as the DeWorm3 project, and also shares his thoughts on the progress made in the this field since the Centre’s inception.
It is considered that we’re in the endgame for many NTDs, with effective implementation of treatments and control measures being a priority. Roy shares his extensive expertise on this topic – from the development of a schistosomiasis vaccine to the need for sustainable economic models to eliminate these diseases.
Are we on track to eliminate or eradicate several NTDs by 2020, as per the WHO’s Roadmap? Find out in IDH's 3 part interview with Sir Roy below.
This interview is part of special month long focus on NTD's by Infectious Diseases Hub which includes an article by researchers from the DeWorm3 project. By bringing together reseach expertise from Imperial College London, LSHTM and the Natural History Museum, DeWorm3 is an exemplar model of the collaborative approach adopted by LCNTDR.
Part 1
00.15 – First, could you introduce yourself and the London Centre for Neglected Tropical Disease Research?
03.08 – Why do you think an interdisciplinary approach is important in helping the NTD field progress?
Part 2
00.17 – 2012 saw the London Declaration on NTDs – 5 years on, what progress has been made?
03.43 – There’s also some interesting work on the schistosomiasis vaccine, could you tell us a bit more about this?
Part 3
00.17 – 2012 saw the London Declaration on NTDs – 5 years on, what progress has been made?
03.43 – There’s also some interesting work on the schistosomiasis vaccine, could you tell us a bit more about this?